We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration.We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanised TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. These TCRs are directed at multiple target classes, many of which have never been worked on before.

Based in


Created in

> Website


#Biotech 11.2023


Sofinnova Partners, F-Prime Capital, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures & the University of Cambridge Venture Fund